Browse Studies — Arctuva

Phase 3

An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; Anti- BCMA x Anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients With Relapsed/Refractory Multiple Myeloma (LINKER-MM3)

This study is researching an experimental drug called linvoseltamab, also called REGN5458. Linvoseltamab has previously been studied by itself (without other …

Relapsed Refractory Multiple Myeloma (RRMM)

Estimated

~$10 – $8,750

Regeneron PharmaceuticalsNCT05730036

Phase 2

A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

To learn if low doses of radiation therapy can help the drug elranatamab enhance the killing effect of the cancer cells.

Phase 2Radiotherapy-Induced Immune PrimingElranatamab+4 more

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT07382739

Phase 2

A Phase 2 Study of Elranatamab in Combination With Isatuximab (ELISA) in Relapsed and Refractory Multiple Myeloma

This is an open-label phase 2 study of elranatamab in combination with isatuximab administered subcutaneously in patients with relapsed and refractory multiple…

Relapsed Refractory Multiple Myeloma (RRMM)Relapsed Refractory Multiple Myeloma

Estimated

~$10 – $6,250

Massachusetts General HospitalNCT06832865

Phase 1

MAGENTA: Phase I Study of Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma

This is a phase 1 study to find the recommended dose and schedule of mezigdomide and talquetamab in relapsed and refractory multiple myeloma (RRMM), and to tes…

Relapsed Refractory Multiple Myeloma (RRMM)

Estimated

~$10 – $6,250

Massachusetts General HospitalNCT07032714